Safety and tolerability of apomorphine SL in patients with erectile dysfunction

被引：20

作者：

Buvat, J

Montorsi, F

机构：

[1] CETPARP, F-59000 Lille, France

[2] San Raffaele Sci Inst, Div Urol, I-20132 Milan, Italy

来源：

BJU INTERNATIONAL | 2001年 / 88卷

关键词：

D O I：

10.1046/j.1464-4096.2001.00127.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：30 / 35

页数：6

共 5 条

[1] Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction [J].

Dula, E ;

Bukofzer, S ;

Perdok, R ;

George, M .

EUROPEAN UROLOGY, 2001, 39 (05) :558-563

[2]

FAGAN TC, 2001, IN PRESS AM J CARDIO

[3] IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].

FELDMAN, HA ;

GOLDSTEIN, I ;

HATZICHRISTOU, DG ;

KRANE, RJ ;

MCKINLAY, JB .

JOURNAL OF UROLOGY, 1994, 151 (01) :54-61

[4] Apomorphine: an update of clinical trial results [J].

Heaton, JPW .

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2000, 12 (Suppl 4) :S67-S73

[5] Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study [J].

Johannes, CB ;

Araujo, AB ;

Feldman, HA ;

Derby, CA ;

Kleinman, KP ;

McKinlay, JB .

JOURNAL OF UROLOGY, 2000, 163 (02) :460-463

← 1 →